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Oncogenic ALKF1174L drives tumorigenesis in cutaneous
squamous cell carcinoma
Marco Gualandi1 , Maria Iorio1,2, Olivia Engeler1, Andre´ Serra-Roma1 , Giuseppe Gasparre2, Johannes H Schulte3,4,5,
Daniel Hohl6 , Olga Shakhova1
Cutaneous squamous cell carcinoma (cSCC) is the second most
common skin cancer characterized by increased mortality. Here,
we show for the first time that anaplastic lymphoma kinase (ALK),
a receptor tyrosine kinase of the insulin receptor superfamily,
plays a pivotal role in the pathogenesis of cSCC. Our data
demonstrate that the overexpression of the constitutively active,
mutated ALK, ALKF1174L, is sufficient to initiate the development of
cSCC and is 100% penetrant. Moreover, we show that cSCC de-
velopment upon ALKF1174L overexpression is independent of the
cell-of-origin. Molecularly, our data demonstrate that ALKF1174L
cooperates with oncogenic KrasG12D and loss of p53, well-
established events in the biology of cSCC. This cooperation re-
sults in a more aggressive cSCC type associated with a higher
grade histological morphology. Finally, we demonstrate that
Stat3 is a key downstream effector of ALKF1174L and likely plays a
role in ALKF1174L-driven cSCC tumorigenesis. In sum, these findings
reveal that ALK can exert its tumorigenic potential via cooper-
ation with multiple pathways crucial in the pathogenesis of cSCC.
Finally, we show that human cSCCs contain mutations in the ALK
gene. Taken together, our data identify ALK as a new key player in
the pathogenesis of cSCC, and this knowledge suggests that
oncogenic ALK signaling can be a target for future clinical trials.
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Introduction
Anaplastic lymphoma receptor kinase (ALK) alterations have been
identified in several human cancers, including neuroblastoma,
glioblastoma, lung cancer, anaplastic large cell lymphoma, and
renal cell carcinoma (Hallberg & Palmer, 2013). Most cancer-
associated rearrangements in the ALK gene are associated with
fusions, copy-gain number, or activating ALKmutations (Hallberg &
Palmer, 2013). In mice, overexpression of the mutated ALKF1174L gene
results in neuroblastoma development (Heukamp et al, 2012). An
elevated expression of phosphorylated ALK as well as its ligands,
midkine, and pleiotrophin has been found in patients with basal
cell carcinoma (BCC) and cSCC (Ning et al, 2013). To investigate the
possible role of ALK in the pathogenesis of skin tumors, we
overexpressed ALKF1174L in the epithelial cells in the skin. A number
of studies has addressed the cell-of-origin of BCC and cSCC. BCC can
arise from the progenitor cells of the interfollicular epidermis, cells
in the infundibulum of the hair follicle (HF) (Youssef et al, 2010), and
HF stem cells (Grachtchouk et al, 2011). Similarly, compelling evi-
dence suggests that cSCC can also arise not only from interfollicular
epidermis but also from the HF stem cells (Lapouge et al, 2011; White
et al, 2011; Sanchez-Danes & Blanpain, 2018). Based on these
studies, we have decided to overexpress ALKF1174L in HF stem cells
using Lgr5-CreERT2 (Barker et al, 2007) and K15-CreERT2 (Morris et al,
2004) mouse lines, and in all basal cells taking advantage of K5-
CrePR1 (Zhou et al, 2002) and K14-CreERT2 (Vasioukhin et al, 1999)
transgenic strains.
Results and Discussion
We induced the expression of ALKF1174L via topical administration
of 4-hydroxytamoxifen (4-OHT) on the shaved back skin as well as
on the ears and tails (Fig 1A). 100% of ALKF1174L Lgr5-CreERT2 mice
developed skin lesions and had to be euthanized at the latest 4
mo after 4-OHT induction (Figs 1B and S1A). Skin lesions became
apparent after 3 wk after transgene activation. Whereas 83% (11/
13 mice) of ALKF1174L Lgr5-CreERT2 mice developed lesions in the
ears and 69% (9/13 mice) in the tail, no abnormalities were seen
in the back skin (Fig 1C). However, skin lesions on the back skin
were occasionally observed in several ALKF1174L overexpressing
mice carrying fight wounds (Fig S1B). It is widely accepted that
epithelial cancers arise as a result of a multistep process in-
volving tumor initiation, promotion, and progression (Hennings &
Boutwell, 1970; Abel et al, 2009). The fact that skin wounding in
combination with other inducing agents has been previously
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demonstrated to promote skin carcinogenesis (Hoste et al, 2015)
suggests that whereas ALKF1174L overexpression alone is sufficient
to drive tumor formation in ear and tail skin, it might require an
additional promoting treatment in the back skin. We nevertheless
excluded those mice from further analysis because our study
focused on the dissection of the role of ALKF1174L overexpression
in the context of skin homeostasis. ALK overexpression was
confirmed using Western blot with anti-pALK antibodies (Fig S1C).
The presence of the luciferase (luc) reporter gene in the ALK
transgene allowed us to monitor tumor development using IVIS
imaging system (Heukamp et al, 2012) (Fig 1D). Based on the
histological examination (Gleich et al, 2016), we distinguished
four types of skin lesions, including cysts (n = 5 mice),
acanthopapilloma (AP) (n = 7 mice), keratoacanthoma (KA) (n = 7
mice), and cSCC type 1 (n = 8 mice) (Figs 1E and F and S1D and E).
Similarly, the targeted expression of ALKF1174L using another HF
stem cell–specific Cre line, K15-CrePR1 (Morris et al, 2004),
resulted in cSCC development (Fig 1G). Moreover, the crossings of
ALKF1174L mice with K5-CrePR1 (Zhou et al, 2002) and K14-CreERT2
(Vasioukhin et al, 1999) lines gave rise to skin lesions strikingly
resembling those present in Lgr5-CreERT2 and K15-CrePR1 lines
as assessed with hematoxylin/eosin staining as well as with an
immunostaining for pan-cytokeratin (pan-Ck) (Figs 1H and I and
S1F). We conclude that ALKF1174L expression alone is sufficient to
drive tumor initiation, and it induces cSCC independently of the
cell-of-origin.
Figure 1. Expression of ALKF1174L in different skin compartments induces skin lesions and cSCC.
(A) Graphical representation of Lgr5-CreERT2;LSL-ALKF1174L genotype and experimental design. Topical application of 4OH-tamoxifen (4-OHT) in ears, back, and tail skin
of mice resulted in skin lesion development. Then, mice were euthanized when termination criteria were observed (tumor size and ulceration). (B) Tumor-free survival of
Lgr5-CreERT2;LSL-ALKF1174Lmice (n = 15, median 47 d) and controls (n = 12). Log-rank (Mantel–Cox) Test P < 0.0001, HR 28.12. All mice developed tumors. (C) From left to right.
Topical administration of 4-OHT and after tumor formation per location. (D) Representative picture of in vivo imaging system (IVIS). Analysis of the LSL-ALKF1174L
transgene expression shows strong luminescent signal from the tumors on ears and tail. (E) Pie chart representing the number of mice that developed the listed skin
lesions out of total skin lesions diagnosed. (F) Representative hematoxylin and eosin (H&E) staining of such lesions from the ears. Scale bars = 100 µm. To note, eachmouse
developed several tumors. (G, H, I) Top to bottom. Genotypes, representative pictures of the tumors marked by pan-cytokeratin immune-labeling and tumor
distribution per location. To note, because of leakage of the Cre expression, tumor formation was observed when no specific topical administration was performed. Scale
bars = 250 µm.
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Next, we examined the expression of ALK protein in the normal
human skin. ALK expression was readily detected in virtually all
basal keratinocytes (Fig S2A). Given the fact that ALK expression in
humans has been described in both tumor types, BCC and cSCC, it
was surprising that we did not observe any signs of BCC devel-
opment in our mouse model. To investigate whether mutations in
ALK gene are present in the human cSCC samples, we performed the
analysis of publicly accessible data resources. Cohen et al (2015)
described the landscape of mutations detected in cSCC diagnosed
in patients undergoing BRAF inhibitor therapy for advanced met-
astatic melanoma and among other mutations, they have detected
the ALKF1174L mutation (1/29 patients). This prompted us to inves-
tigate the frequency of ALK mutations in primary and metastatic
human cSCC, and we focused on analysis of human cSCC using
exome sequencing (Fig S2B) (Durinck et al, 2011; Lee et al, 2014;
Pickering et al, 2014; Li et al, 2015; Yilmaz et al, 2017; Inman et al,
2018). Of 161 human cSCC cases analyzed, we have identified 32
cases (20%) carrying mutations in the ALK gene. PolyPhen-2 soft-
ware was used to predict damaging effects of identified ALK mu-
tations (Fig S2C) (Adzhubei et al, 2010). Whereas nearly 50% of cases
predicted no effect on the ALK gene function, others were char-
acterized as potentially harmful mutations. Of note, in addition to
the p.F1174L mutation identified in cSCC occurring in the melanoma
patient (Cohen et al, 2015), two additional cases harbored the
p.G1201E (Murugan & Xing, 2011) and p.G1286R (Bresler et al, 2014)
mutations, which are known ALK gain-of-function mutations (Fig
S2C). We also checked for the presence of mutations in the Alk gene
in the previously described mouse models of cSCC (Nassar et al,
2015). Two mutations were described, namely, the p.C787S and the
p.C1012S, which, however, did not correlate with Alk expression
(Nassar et al, 2015).
To directly assess whether the AlkF1178L (orthologue to ALKF1174L)
mutation is present in mouse cSCC, we have sequenced exon 23 of
the Alk gene from six independent cSCC induced by a combination
of DMBA (7,12-dimethylbenzanthracene) and TPA (12-O-
tetradecanoylphorbol-13-acetate) treatment (Fig S2D). None of
the tumors exhibited mutations in the Alk gene. This could be due
to the fact that all mouse DMBA/TPA tumors are induced on the
back skin, a location devoid of skin lesions in ALKF1174L over-
expressing mice. Because DMBA/TPA–induced tumors are pre-
dominantly driven by oncogenic mutations in RAS signaling, an
alternative explanation may be that ALK and RAS are mutually
exclusive drivers of skin tumorigenesis. To test this hypothesis, we
have analyzed the co-occurrence and overall frequency of ALK
and RAS mutations in human cSCC using cBio Portal (Fig S2E).
Among all RAS genes analyzed, we have observed that mutations
in ALK gene appear to be mutually exclusive with mutations in
KRAS gene (68 cases analyzed and 0 cases display co-occurrence).
Mutations in HRAS and NRAS genes co-occurred with mutations in
ALK in some cases (68 cases analyzed, 1 case co-occurrence of
NRAS and ALK in the same patient, and 3 cases show co-
occurrence of ALK and HRAS mutations).
Furthermore, we ruled out the possibility that the back skin of
ALKF1174L Lgr5-CreERT2 mice contained early lesions, yet not visible
to the naked eye. To this aim, we performed thorough histological
and immunohistochemical examination with anti-Ki67 antibodies
and quantified the proliferation index of keratinocytes identified by
pan-Ck staining (Fig S3B). Even though some HF appeared dys-
plastic, no increased proliferation was observed.
To dissect the molecular mechanisms underlying the ALKF1174L-
driven cSCC in the skin, we isolated tumor epithelial cells (TECs)
from ALKF1174L lesions and normal keratinocytes from their
wild-type littermates by FACS using a combination of
Epcam+CD31−CD45−CD140a− markers as previously described
(Nassar et al, 2015) and independent triplicates were subjected to
RNA sequencing (Fig 2A). Analysis of differentially expressed ker-
atins revealed a pronounced decrease in the expression level of
Krt77 (Krt 1b) and Krt15, indicative of an impaired epithelial dif-
ferentiation (Fig 2C). On the other hand, several other keratins,
including Krt6, Krt7, Krt17, and Krt18 were significantly increased.
Krt6, Krt16, and Krt17 are associated with aberrant proliferation, and
Krt18 is a marker of embryonal keratinocytes and is often associ-
ated with poor differentiation and epithelial-to-mesenchymal
transition (EMT) in cSCC (Fig 2C) (Watanabe et al, 1995). Gene on-
tology (GO) term analysis provided further insights into biological
processes enriched in ALKF1174L TECs. Among significantly up-
regulated processes were cell adhesion/migration and prolifera-
tion, along with alterations in metabolic processes (Fig 2B and E).
The latter overall indicated a shift towards an anabolic and gly-
colytic (Warburg-like) metabolic phenotype, an additional hallmark
that ALKF1174L cells would gain in support of transformation. In
addition, Kyoto Encyclopeida of Genes and Genomes (KEGG)
analysis revealed ALKF1174L-associated signature including alter-
ations in several signaling pathways including FAK and ECM, PI3K-
AKT, and JAK-STAT3 (Fig 2B and D). Moreover, ALKF1174L expression
resulted in an increase of Mek1 (Map2k1) expression (Fig 2D and F).
Interestingly to note is that this signaling signature has been de-
scribed as characteristic of cSCC development (Ratushny et al,
2012). The expression profile of ALKF1174L-driven tumorigenesis re-
veals the lack of Sonic Hedgehog (Shh) signaling pathway, which is
characteristic of the typical BCC, demonstrating that ALKF1174 ex-
pression leads to cSCC formation without any cellular and mo-
lecular signs of concomitant BCC development.
Similarly to the DMBA/TPA model of mouse carcinogenesis,
human SCCs are often associated with mutations in the RAS genes
(van der Schroeff et al, 1990; Spencer et al, 1995). Overexpression of
either Hras or Kras in mouse skin initiates tumorigenesis (Brown
et al, 1998; Vitale-Cross et al, 2004; Caulin et al, 2007). The analysis of
RNA-seq data obtained from the comparison of WT ear keratino-
cytes and ALKF1174L TECs did not reveal any significant deregulation
in the Ras signature. Moreover, our data on the co-occurrence of
mutations in RAS and ALK genes in human patients did not reveal
any strong evidence suggesting that ALK and RAS are mutually
exclusive drivers of cSCC (Fig S2E). Thus, we sought to functionally
determine whether ALKF1174L can cooperate with Kras in driving SCC
development. To answer this question, we have crossed ALKF1174L
Lgr5-CreERT2 mice with KrasG12D strain (Fig 3A) (Jackson et al, 2001).
Within less than 40 d, all mice developed ulcerative lesions on the
ears and tails (n = 13) (Fig 3B and E). As shown in Fig 3B, the tumor
penetrance/incidence remained as high as in the ALKF1174L trans-
gene and reached 92% in ear and tail areas. However, similarly to
ALKF1174L overexpression, no tumors were seen in the back skin of
ALKF1174LKrasG12D Lgr5-CreERT2 mice. In analogy to ALKF1174L Lgr5-
CreERT2 mice, the histological analysis revealed the presence of
ALK in cutaneous squamous cell carcinoma Gualandi et al. https://doi.org/10.26508/lsa.201900601 vol 3 | no 6 | e201900601 3 of 14
Figure 2. ALKF1174L–driven tumorigenesis relied in bona fide, via PI3K-AKT/focal adhesion–ECM receptor interaction pathways.
(A) Ear tumor from Lgr5-CreERT2;LSL-ALKF1174L mice and ears from control mice were prepared as a single-cell suspension. Tumor cells and keratinocytes were isolated
by FACS for EpCAM expression e-negative selected for CD31/CD45/CD140a. RNA was extracted from sorted cells and used for RNA sequencing (RNA-seq). (B) Top 15
biological processes and KEGG signaling pathways of up- and down-regulated genes from RNA-seq transcriptional profiling of sorted tumor cells versus normal
keratinocytes. (C) Significantly deregulated keratins. (D) Genes significantly altered that cluster in the PI3K-AKT, Jak-Stat, and focal adhesion–ECM receptor interaction
KEGG signaling pathways. (E) Clustering of biological processes using the MSigDB c5.bp.v6.2 gene set. Red nodes represent up-regulated gene sets and blue nodes
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four distinct histological entities including, cysts, AP, KA, and SCC1
(Figs 3C and S3C–E). The addition of KrasG12D transgene resulted in
an increased number of tumors per mouse as compared with
ALKF1174L Lgr5-CreERT2 mice (Fig 3D). Moreover, ALKF1174LKrasG12D
Lgr5-CreERT2mice showed signs of aggressive SCC (size, ulceration,
and bleeding) at earlier time points as compared with ALKF1174L
Lgr5-CreERT2 mice (median 19 d post induction versus 37, d re-
spectively, P < 0.0001) (Fig 3F). Taken together, these data strongly
suggest that KrasG12D oncogene cooperates with ALKF1174L in driving
the pathogenesis of cSCC.
To determine the molecular mechanisms underlying this co-
operative effect, we have isolated TECs from tumors of ALKF1174L
Lgr5-CreERT2 and ALKF1174LKrasG12D Lgr5-CreERT2 (Fig 3G) using
previously described FACS protocol (Nassar et al, 2015) and per-
formed RNA sequencing. GO and KEGG analysis highlighted several
major alterations upon the addition of KrasG12D oncogene (Fig 3H–J).
Among these, cell adhesion/migration and ECM remodeling were
suggestive of an EMT process initiated upon KrasG12D. To further test
it, we performed immunostaining for vimentin, a mesenchymal
marker, and quantified the number of cells double positive for pan-
CK and vimentin (Fig 3K). As shown in Fig 3L, double transgenic
ALKF1174LKrasG12D Lgr5-CreERT2mice showed higher number of pan-
Ck+/Vim+ cells as than single ALKF1174L transgene (n = 5; 5, P = 0.0117,
mean ± SD: 4.907 ± 2.904; 8.547 ± 3.885). Furthermore, based on our
RNA-seq data, double transgenic TECs displayed an increased
proliferation. To verify this, we performed immunostaining for Ki67,
a marker of cell proliferation and quantified number of Pan-Ck+/
Ki67+ cells within tumors (Fig 3M and N). Indeed, in alignment with
RNA-seq data, we show that KrasG12D oncogenic induction resulted
in a pronounced increase in the proliferative index of cancer cells.
In addition, among the most significantly regulated keratins, we
identified Krt4, Krt8, and Krt19 strongly up-regulated in
ALKF1174LKrasG12D TECs (Fig S3F). Krt4, Krt8, and Krt19 were previously
described as keratins associated with stem cell potential, dedif-
ferentiation, proliferation, and invasion (Watanabe et al, 1995). To
examine the degree of vascularization within individual tumors, we
used a well-defined marker of angiogenesis, CD31, and quantified
its relative expression (Fig 3O and P). Our results revealed that
KrasG12D significantly increased the expression of CD31, suggesting
the presence of enhanced vascularization in tumors of
ALKF1174LKrasG12D Lgr5-CreERT2mice. Thus, the cooperation between
ALKF1174 and KrasG12D, leading to the more aggressive type of cSCC,
manifests through a combination of cellular mechanisms, including
induction of EMT, increase in, proliferation and enhanced
vascularization.
To delve further into the question of whether DMBA/TPA tumors
exhibit molecular signature similar or distinct of the one observed in
ALK-driven cSCC, we compared genetic profiles of ALKF1174L TECs to the
previously published signature of DMBA/TPA tumors (Nassar et al,
2015) (Figs S4 and S5). 302 overlapping genes emerged as a result of
this comparison, including 85 commonly up-regulated and 206
down-regulated (Fig S4A and C). The analysis of Ras-associated
pathways in both mouse models confirms our previous ob-
servations and reveals that ALK executes a specific pro-tumorigenic
program that is distinct of Ras-driven cSCC (Fig S4B and D).
Functional loss of TP53 gene is a hallmark of human SCC (van
Kranen et al, 1995), and loss of p53 gene combined with KrasG12D
overexpression promotes invasive SCC in mice (Lapouge et al, 2011;
White et al, 2011). Our analysis of human cSCC patients (Fig S2E)
revealed the co-occurrence between ALKmutations and mutations
in p53 gene (68 cases analyzed, 0 cases displayed ALK only mu-
tations, and 19 cases displayed mutations in both genes). To de-
termine whether the loss of p53 can promote metastases in
ALKF1174-driven model of SCC, we have crossed ALKF1174L Lgr5-
CreERT2 mice to p53fl/fl allele (Marino et al., 2000) (Fig 4A). Neither
tumor-free survival nor progression-free survival were significantly
altered upon p53 loss (Fig 4B and C). However, the frequency of
tumors per mouse was increased in p53fl/fl as compared with
ALKF1174 single transgene (Fig 4D). Histological examination revealed
several p53 loss–associated alterations. In addition to a higher
degree of nuclear atypia, tumors isolated from ALKF1174Lp53fl/fl Lgr5-
CreERT2 mice contained not only cysts, KA, AP, and SCC1 but also
included more aggressive histological subtypes, AP3 and SCC2 (Figs
4E and F and S6A–C). Because p53 loss leads to an invasive cSCC in
several mouse models of cSCC, we decided to investigate whether
tumors obtained from ALKF1174Lp53fl/fl Lgr5-CreERT2 mice were
characterized by a change in the EMT signature. We have decided to
evaluate the expression of vimentin, a protein which is not only
expressed at low levels in the dermal cells of the skin but is also one
of markers of cells undergoing EMT (White et al, 2011). The quan-
tification of the relative number of Vim+/Pan-Ck+ cells within these
tumors highlighted the presence of a greater number of cells with
invasive characteristics, particularly in SCC2 (Fig 4G). The recom-
bination in p53 floxed allele was verified using PCR analysis as
shown in Fig 4H (Marino et al., 2000). In summary, these data in-
dicate that the p53 loss resulted in the most aggressive histological
subtype of ALKF1174L-driven primary SCC. Our data are in agreement
with several other reports demonstrating that KrasG12D when
combined with the loss of p53 gene results in a spindle cell, high-
grade SCC (Lapouge et al, 2011; White et al, 2011, 2014; White & Lowry,
2011).
Tomonitor metastases, we took the advantage of the presence of
luc reporter gene and subjected ALKF1174Lp53fl/fl Lgr5-CreERT2 mice
to an in vivo live imaging at the time point when the termination
criteria were met and before euthanizing (n = 7). As shown in Fig 4I,
luciferase expression was readily detected in the skin as well as in
the gut of ALKF1174Lp53fl/fl Lgr5-CreERT2 mice. However, no signs of
distant metastases were detected in the internal organs (Fig 4I).
This could be explained either by strict termination criteria of our
study or low sensitivity of IVIS imaging, and therefore, we cannot
completely rule out the occurrence of micrometastases with pa-
rameters under our instrumental detection limits.
Among down-regulated genes upon ALKF1174L overexpression, we
have identified that several inhibitors of signal transducer and
represent gene sets down-regulated in the tumor cells. Node size shows the size of gene sets. Nodes that clustered together are classes with same or similar function
indication. Lines between the nodes represent association of the gene sets within the nodes. (F) Graphical representation of genes/pathways regulated by ALKF1174L, based
on RNA-seq data.
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Figure 3. KrasG12D synergizes with ALKF1174L increasing tumorigenicity, epithelial-to-mesenchymal transition properties, and vascularization and proliferation.
(A) Graphical representation of Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D genotype. (B) Distribution of tumor formation per location in Lgr5-CreERT2;LSL-ALKF1174L;LSL-
KrasG12D mice. (C) Pie chart representing the number of mice that developed the listed skin lesions out of total lesions diagnosed. (D) Number of tumors per mouse in
Lgr5-CreERT2;LSL-ALKF1174L and Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12Dmice. Each dot represents the number of tumors permouse. Mean ± standard error of themean (5.917
± 1.026; n = 12; 10.67 ± 1.280 n = 9; two-tailed t test P = 0.0086). (E) Tumor-free survival of Lgr5-CreERT2;LSL-ALKF1174L (n = 15, median 47 d) and Lgr5-CreERT2;LSL-ALKF1174L;LSL-
KrasG12D (n = 13, median 29 d) mice. Log-rank (Mantel–Cox) test; P = 0.0002, HR = 0.1461. (F) Progression-free survival of Lgr5-CreERT2;LSL-ALKF1174L (n = 15, median 37 d) and
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activator of transcription 3 (Stat3) were altered. We have observed
down-regulation of the protein inhibitor of activated STAT, Pias3, a
specific inhibitor of Stat3, which prevents DNA-binding activity of
Stat3 and thereby abolished Stat3-mediated transcription (Chung
et al, 1997). Moreover, the expression of another inhibitor of Stat3,
Socs7 (Martens et al, 2005), was also decreased (Fig 2D). In addition,
the expression of the tyrosine phosphatase Ptpn6 (Shp1), which
was shown to dephosphorylate Stat3 but not Stat1 or Stat5
(Demosthenous et al, 2015), was also changed based on our RNA-
seq results. Previous reports showed that the expression of con-
stitutively active form of Stat3 driven by the K5 promoter (K5.Stat3C
mice) resulted in an increased number of tumors as well as a
shorter latency period after DMBA/TPA treatment (Chan et al, 2008)
and Stat3-deficient mice are resistant to chemically induced car-
cinogenesis (Chan et al, 2004).
Based on these observations, we hypothesized that expression
of ALKF1174L may trigger Stat3. To test this, we analyzed the protein
homogenates from several ALKF1174L and ALKF1174LKrasG12D tumors
with anti-Y705-Stat3 and anti-S727-Stat3 antibodies using Western
blot (Fig 5A). The vast majority of tumors showed phosphorylation
of Stat3, whereas Stat3 KO ES cells were devoid of any signal. To
evaluate whether ALKF1174L overexpression can lead to phosphor-
ylation of Stat3, we compared HEK293T cells transiently over-
expressing the mutated ALK (pCMV-ALKF1174L) with their
corresponding mock control (pCMV6-entry). As shown in Fig 5B, the
overexpression of ALKF1174L in HEK293T cells resulted in Stat3
phosphorylation. On the basis of these results, we reasoned that
Stat3 might play an essential role in mediating ALKF1174L-driven SCC
formation. To test this possibility, we have crossed ALKF1174L Lgr5-
CreERT2mice to conditional Stat3 knockout mice (Jacoby et al, 2003)
(Fig 5C). ALKF1174L Stat3fl/fl Lgr5-CreERT2 showed prolonged tumor-
free survival and progression-free survival as compared with
ALKF1174L Lgr5-CreERT2 mice. However, tumor formation still oc-
curred (Fig 5D and E). We verified the presence of the recombined
Stat3 floxed allele using PCR strategy (Moh et al, 2007) (Fig 5F). The
resulting data revealed that 3/6 analyzed tumors from ALKF1174L
Stat3fl/fl Lgr5-CreERT2 mice were partially recombined and 3/6
tumors revealed the lack of the Stat3 recombined allele (Fig 5F),
suggesting that the recombination was partial. To test whether the
resulting tumors were still expressing Stat3, we have performed
immunostaining for p-Stat3 and observed that 100% of tumors still
contained Stat3-positive cells (Fig 5G). This observation is in
alignment with the data obtained from the analysis of the re-
combination efficiency (Fig 5F). We next evaluated the percentage
of the recombination and counted the number of HF either positive
or negative for p-Stat3 protein (all WT HF were devoid of p-Stat3).
Whereas the vast majority of HFs in ALKF1174L Lgr5-CreERT2 mice
showed readily detectable p-Stat3 protein, less than 50% of HF were
positive for p-Stat3 in ALKF1174L Stat3fl/fl Lgr5-CreERT2 mice (Figs 5H
and S6D). It is plausible that these p-Stat3–positive HFs occurred
because of the low recombination efficiency and likely give rise to
the tumors observed.
Although our data suggest that ALKF1174L-mediated tumorigen-
esis, at least in part, might occur via its downstream effector STAT3,
further experimental evidence is required to determine the sig-
nificance of these findings.
Our findings reveal a previously unknown role of oncogenic ALK
signaling in cSCC. We show that the expression of a constitutively
active ALKF1174L in mice can lead to the development of aggressive
forms of cSCC (Fig 6). On themolecular level, ALKF1174L can cooperate
with known cSCC drivers, including KrasG12D as well with the loss of
tumor suppressor p53. Moreover, our data demonstrate that Stat3 is
essential for mediating the oncogenic effect of ALKF1174L. In addition
to our data uncovering the essential role of oncogenic ALKF1174L in
mouse cSCC, we show that human samples of cSCC contain ALK
mutations as well. Therefore, our data provide a rational for on-
cogenic ALK as a novel therapeutic target and can serve as a basis
for the design of future clinical trials.
Materials and Methods
Transgenic mice
All animal experiments have been approved by the cantonal vet-
erinary authorities of Zurich, in accordance with Swiss laws. For DNA
isolation, mouse biopsies were lysed using lysis buffer (5M NaCl, 2M
Tris, pH 88.5, 0.5M EDTA, and 20% SDS) and proteinase K. DNA was
Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D (n = 13, median 19 d) mice. Log-rank (Mantel–Cox) test; P < 0.0001, HR = 0.07945. (G) Ear tumor from Lgr5-CreERT2;LSL-ALKF1174L;LSL-
KrasG12D mice were prepared as a single-cell suspension, and tumor cells were isolated by FACS for EpCAM expression e-negative selected for CD31/CD45/CD140a. RNA
from sorted cells was used for RNA-seq. (H) Above: Venn diagram representing deregulated genes in tumor cells over controls. Below: significantly altered genes in Lgr5-
CreERT2;LSL-ALKF1174L;LSL-KrasG12D over Lgr5-CreERT2;LSL-ALKF1174L tumor cells. (I) Significantly altered biological processes and KEGG signaling pathways in Lgr5-CreERT2;
LSL-ALKF1174L and Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D tumors. Horizontal columns represent the P-value of the analysis of the up-regulated genes from RNA-seq
transcriptional profiling of sorted tumor cells versus normal keratinocytes. Processes and pathways marked by * are significantly changed also in the analysis of
transcriptomes of Lgr5-CreERT2;LSL-ALKF1174L versus Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D tumor cells. (J)Genes significantly regulated from RNA-seq analysis, between
Lgr5-CreERT2;LSL-ALKF1174L and Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D tumor cells that cluster in the indicated KEGG signaling pathways. (K) Representative
immunofluorescences of Lgr5-CreERT2;LSL-ALKF1174L and Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D ear tumors immuno-labelled with DAPI, pan-cytokeratin (Pan-Ck), and
vimentin antibodies. (L) Cells that co-expressed Pan-Ck and vimentin were counted as cells in epithelial-to-mesenchymal transition. Every tumor arising in the mice
was analyzed and relative quantification is represented by a dot. Analysis of tumors from five Lgr5-CreERT2;LSL-ALKF1174L and five Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D
mice showed an increased number of relative vimentin+ cells in Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D tumors (4.907 ± 2.904; 8.547 ± 3.885. Mann–Whitney test P = 0.0117).
Scale bars = 50 µm. (M) Representative immunohistochemistry of Lgr5-CreERT2;LSL-ALKF1174L and Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D ear tumors immuno-labelled
with Pan-Ck and with Ki67 antibodies, to identify tumors and proliferating cells. (N) Analysis of tumors from nine Lgr5-CreERT2;LSL-ALKF1174L and eight Lgr5-CreERT2;LSL-
ALKF1174L;LSL-KrasG12D mice showed an increased relative number of proliferating cells in the Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D tumors (5.786 ± 4.958; 7.614 ± 4.828.
Mann–Whitney test P = 0.0043). Scale bars = 100 µm. (O) Representative immunohistochemistry of Lgr5-CreERT2;LSL-ALKF1174L and Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D
ear tumors immuno-labelled with Pan-Ck and with CD31 antibodies, to identify tumors and vessels. (P) Every tumor arising in the mice was analyzed and relative
quantification is represented by a dot. Analysis of tumors from eight Lgr5-CreERT2;LSL-ALKF1174L and eight Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D mice showed an
increased relative area occupied by vessels within the Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D tumors (30.75 ± 34.34; 46.10 ± 35.24. Mann–Whitney test P = 0.0035). Scale
bars = 100 µm. (J, K, L) Data showed as mean ± SD.
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Figure 4. p53 conditional KO increased tumorigenicity driven by ALKF1174L.
(A) Graphical representation of Lgr5-CreERT2;LSL-ALKF1174L;p53fl/fl genotype. (B) Tumor-free survival of Lgr5-CreERT2;LSL-ALKF1174L (n = 15, median 47 d) and Lgr5-CreERT2;
LSL-ALKF1174L;p53fl/fl (n = 20, median 49 d)mice. Log-rank (Mantel–Cox) test; P = 0.4998, HR = 0.7834. (C) Progression-free survival of Lgr5-CreERT2;LSL-ALKF1174L (n = 15, median
37 d) and Lgr5-CreERT2;LSL-ALKF1174L;p53fl/fl (n = 20, median 32 d) mice. Log-rank (Mantel–Cox) test; P = 0.4158, HR = 0.7478. (D) Number of tumors per mouse in Lgr5-CreERT2;
LSL-ALKF1174L and Lgr5-CreERT2;LSL-ALKF1174L;p53fl/flmice. Each dot represents the number of tumors in a specific mouse. Mean ± standard error of themean (5.917 ± 1.026;
n = 12; 10.12 ± 1.3 n = 17; Two-tailed t test P = 0.0254). (E) Pie chart representing the number of mice that developed the listed skin lesions out of total lesions diagnosed. (F)
Representative hematoxylin and eosin (H&E) staining of acanthopapilloma3 and multiple SCC2 from ear skin of Lgr5-CreERT2;LSL-ALKF1174L;p53fl/fl mice. In the
magnification, it is possible to appreciate mesenchymal-like features of tumor cells and pronounced nuclear atypia. Scale bars = 100 µm. (G) Representative
immunofluorescences of Lgr5-CreERT2;LSL-ALKF1174L;p53fl/fl ear tumor immuno-labelled with DAPI, pan-cytokeratin (Pan-Ck), and vimentin antibodies. Scale bar = 50 µm.
Cells that co-expressed Pan-Ck and vimentin were counted as cells in epithelial-to-mesenchymal transition (EMT). All tumors diagnosed as cSCC type 1 or 2 from different
mice were analyzed, and quantification of the relative number of cells in EMT per tumor is represented by a dot. Analysis of tumors showed that no significant changes
were observed between SCC1 tumors of three Lgr5-CreERT2;LSL-ALKF1174L or three Lgr5-CreERT2;LSL-ALKF1174L;p53fl/flmice (4.380 ± 1.425; 7.360 ± 1.996. Mann–Whitney test P =
0.3277). Strong increase in the EMT rate was instead noted in SCC2 tumors when compared with SCC1 tumors of the same cohort of mice (7.360 ± 1.996; 17.10 ± 1.875.
Mann–Whitney test P = 0.0056) or to Lgr5-CreERT2;LSL-ALKF1174L mice (4.380 ± 1.425; 17.10 ± 1.875. Mann–Whitney test P = 0.0008). All values are showed as median with
95% confidence interval. (H) Above: the schematic structure of the p53 floxed allele and graphical representation of PCR strategy to determine the recombination
efficiency of LoxP sites that drives the removal of exons 2–10 of the p53 gene. White boxes represent exons, arrowheads represent the LoxP sites, and purple lines indicate
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precipitated in 50% lysate and 50% isopropanol and centrifuged at
20.817g for 30 min. After washing in 70% ethanol, 2 µl of DNA were
mixed with 10 µl KAPA Taq ReadyMix with dye (KK1024; Kapa Bio-
systems) and with 0.8 µl of each primer (10 µM) and finally brought
to 20 µl with MilliPore water. The following primers with
according melting temperatures were used: 60°C, LSL-ALK_7083_Fw
(CCATCAGTGACCTGAAGGAGG) LSL-ALK_7083_Rv (CACGTGCAGAAGG
TCCAGC), 60°C, Cre_Fw (CTATCCAGCAACATTTGGGCCAGC) Cre_Rv (CC
AGGTTACGGATATAGTTCATGAC), 60°C, LSL-KRAS_Fw1 (TGTCTTTCCC
CAGCACAGT) LSL-KRAS_Rv (CTGCATAGTACGCTATACCCTGT) KRAS_Fw2
(GCAGGTCGAGGGACCTAATA), 55°C, Stat3_floxed_Fw (TTGACCTGT
GCTCCTACAAAAA) Stat3_floxed_Rv (CCCTAGATTAGGCCAGCACA), 60°C,
p53-oIMR8543_Fw (GGTTAAACCCAGCTTGACCA) p53-oIMR8544_Rv
(GGAGGCAGAGACAGTTGGAG), 58°C, iCre-K5_Fw (CTCTGACAGATGCCA
GGACA) iCre-K5_Rv (TCTCTGCCCAGAGTCATCCT), 60°C, K14-CreErt2_T_Fw
(CGCATCCCTTTCCAATTTAC) K14-CreErt2_T_Rv (GGGTCCATGGTGATACAAGG)
K14-CreErt2_C_Fw (CTAGGCCACAGAATTGAAAGATCT) K14-CreErt2_C_Rv
(GTAGGTGGAAATTCTAGCATCATCC) PCRs were run on a Thermocycler
(T300; Biometra) using the following program. 5 min at 95°C, 35 times:
denaturation for 40min at 95°C, annealing for 40min atMT, 40min of
elongation at 72°C, and final elongation for 10 min at 72°C. The PCR
products were run on 2% agarose (in Tris-acetate-EDTA [TAE]) gels
containing RedSafe (21141; JH Science) at 90V until bands were nicely
separated and subsequently visualized using BioDoc-It Imaging
System (Ultra-Violet Products). All transgenic mice used for exper-
iments were maintained in a C57Bl6/129-mixed background.
Lgr5tm1(cre/ERT2)Cle (MGI ID: 3764660), Stat3tm2Aki (MGI ID: 1926816),
and Tg(KRT14-cre/ERT)20Efu (MGI ID: 2446606) were purchased from
The Jackson Laboratory. Tg(Th-ALK*F1174L)2Lochmicewere created in
the Laboratory of Prof. JH Schulte (Berlin, Germany). Tg(KRT5-cre/
PGR)1Der (MGI ID: 2651408) mice were kindly obtained from Labo-
ratory of Prof. M Van Der Broek (Zurich, Switzerland). Tg(Krt1-15-cre/
PGR)22Cot mice were generously got from Laboratory of Prof. Y
Barrandon (Lausanne, Switzerland). Trp53tm1Brn (MGI ID: 1931011)
and B6.129S4-Krastm4Tyj (MGI ID: 2429948) mice were donated by
Laboratory of TR Graft (Zurich, Switzerland). The recombination ef-
ficiency PCRswere performedas previously described for p53 (Marino
et al., 2000) and Stat3 (Moh et al, 2007).
Induction of Cre activity, termination criteria, and in vivo imaging
system
For activation of Cre activity, 6–12-wk-old mice were shaved on
the back skin and 4-Hydroxytamoxifen (4-OHT) 25 mg/ml (≥70% Z
isomer H7904; Sigma-Aldrich) was topically administered for
three consecutive days, using a small paint brush on both ears
(inside and outside), on the tail and on the shaved patch of the
back skin. The mice were euthanized when termination criteria
was reached. In most cases, size of tumors (>0.5 cm of diameter,
n = 2) was the adopted termination criteria. Secondary, mice were
euthanized if developed one tumor bigger than 1 cm of diameter
or if tumor was ulcerative or bleeding. Mice that showed wounds
(signs of fights) were withdrawn from experiment. On the day of
euthanizing, the animals were anesthetized with isoflurane
(B506; Abbott) and shaved with a waxing cream (Veet). Then mice
have been injected with 150 mg/kg body weight of XenoLight
D-Luciferin-K+ Salt Bioluminescent Substrate (122799; Perki-
nElmer) and imaged with IVIS Lumina III (PerkinElmer). In vivo and
ex vivo analysis was performed, and tissue was collected
according with the signal acquired for histological analysis. Skin,
organs, and tumors were embedded in paraffin for immuno-
histochemistry and hematoxylin and eosin staining.
Immunofluorescence and immunohistochemistry and
hematoxylin & eosin (H&E)
Mouse skin and tumor samples were fixed in Roti-Histofix (P078.3;
Roth) for 2 h. Then washed in PBS and embedded in paraffin
(MEDITE PURE Paraffin, 40-0020-00; MEDITE). Sections of 5-μm-
thickness were deparaffinized, rehydrated using the Automated
Staining System AS-2 (SN: 180.001.1015.119; Pathisto), and antigen
retrieval was performed in citrate buffer (pH 6.0, 82% 10-mM
sodium citrate plus 18% of 10 mM citric acid) or in EDTA buffer (pH
8.0, 1 mM EDTA, 0.05% Tween 20) for 25 min at 110°C using
Decloaking Chamber (SN: DG12-220-0134; Biocare Medical). At least
20 independent sections per genotype were histologically scored.
For immunofluorescence assay, the sections were washed with
PBS and incubated in blocking solution (5% horse serum in PBS)
for 1 h. Subsequently, the slides were incubated overnight at 4°C
with the following primary antibodies diluted in PBS: 1:500
monoclonal anti–pan-cytokeratin−FITC (F0397; Sigma-Aldrich), 1:
500 anti-vimentin antibody (ab92547; Abcam), and 1:100 Phospho-
Stat3 (Tyr705) antibody D3A7 (9145S; Cell Signaling Technology).
After washing in PBS, Alexa Fluor 555 goat antirabbit IgG (A21428;
Invitrogen) diluted 1:250 in PBS was applied for 1 h at room
temperature. The sections were washed in PBS and mounted with
DAKO Fluorescent Mounting Medium (S3023; DAKO) containing 1:
1,000 Hoechst 33342 (H1399; Molecular probes by Life Technolo-
gies). Images were captured with Leica DMI6000 B and analyzed
using the LAS X software or with Zeiss Axio Scan.Z1 and processed
with ZEN software. Immunohistochemistry was performed fol-
lowing the instruction of Mouse on Mouse (M.O.M.) Basic Kit
(BMK-2202; Vector Laboratories) combined with the protocol of
ImmPRESS-AP Anti-Rabbit Ig Reagent–Alkaline Phosphatase (MP-
5401-15; Vector Laboratories). Briefly, deparaffinization and anti-
gen retrieval were performed as previously described. M.O.M. kit
was used 1:1,000 monoclonal anti–pan-cytokeratin−FITC (F0397;
Sigma-Aldrich), Anti-Ki67 antibody (15580; Abcam), and 1:1,000
Anti-CD31 antibody (ab182981; Abcam). Detection of the signal was
performed with the Vector Blue Substrate Kit (SK5300; Vector
primers position. Below: PCR analysis of recombination in different tissues. The 612-bp band present in the Lgr5-CreERT2;LSL-ALKF1174L;p53fl/fl tumors confirms that
recombination occurred. (I) Representative pictures of in vivo imaging system (IVIS). Analysis performed to detect metastasis in vivo (left) and ex vivo (right). The grey box is
used to cover a strong luciferase signal in the gut. The strong luciferase expression observed in the intestinal epithelium of the gut is likely due to the residual amount of
4-OHT entering systemic circulation (mice transferring 4-OHT by scratching their ears and subsequently licking their paws).
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Figure 5. Stat3 is indispensable for ALKF1174L-driven tumorigenicity.
(A, B)Western blot analysis of phosphorylation status of Stat3 in (A) Lgr5-CreERT2;LSL-ALKF1174L and Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D tumors and in (B) HEK293T cell
line transiently expressing the ALKF1174L transcript or control. (C) Graphical representation of Lgr5-CreERT2;LSL-ALKF1174L;Stat3fl/fl genotype. (D) Tumor-free survival of Lgr5-
CreERT2;LSL-ALKF1174L (n = 20, median 51 d) and Lgr5-CreERT2;LSL-ALKF1174L;Stat3fl/fl (n = 11, median 63 d) mice. Log-rank (Mantel–Cox) test; P = 0.0202, HR = 2.540. (E)
Progression-free survival of Lgr5-CreERT2;LSL-ALKF1174L (n = 20, median 37 d) and Lgr5-CreERT2;LSL-ALKF1174L;Stat3fl/flmice (n = 11, median 43 d). Log-rank (Mantel–Cox) test;
P = 0.0616, HR = 2.066. (F) Above: structure of the Stat3 floxed allele and graphical representation of PCR strategy to analyze recombination efficiency. Recombined allele
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Laboratories) and DAB Substrate Kit (ab64238; Abcam) or AEC
Substrate system (ab64252; Abcam). The slides were mounted with
DAKO Fluorescent Mounting Medium (S3023; DAKO) and sealed
with nail polish. Images were captured with Zeiss Axio Scan.Z1 and
processed with ZEN software. For H&E, the slides were first
deparaffinized for 20 min in Histo-Clear (D1620333; Chemie
Brunschwig), and then rehydrated for 1 min each in 100%, 96%,
80%, and 70% ethanol and ddH2O. After 10 min in hematoxylin, the
slides were washed for 30 min in tap water, 30 min in Scott Water
(8 mM MgSO4 × 7H2O [M2643-500G; Sigma-Aldrich] and 24 mM
NaHCO3 [S5761; Sigma-Aldrich]), and 1 min in eosin (0.2%, 41-
6660-00; MEDITE) containing three drops of CH3COOH. Subse-
quently, the slides were dehydrated and finally placed for 20 min
in xylol (103746; EBIS). Then, mounting was performed using Eukitt
Quick hardening mounting medium (03989; Fluka). Images were
captured with Zeiss Axio Scan.Z1 and processed with ZEN
software.
Quantifications
Quantification of Vimentin+ and pan-cytokeratin+ cells was per-
formed using a machine learning bio-image analysis software:
QuPath (Bankhead et al, 2017). The software was trained to identify
tumor cells, stromal cells, EMT cells, and false positives. Quanti-
fication of CD31 signal and ki67+ cells over pan-cytokeratin area was
performed with CellProfiler (www.cellprofiler.org), a cell image
analysis software. Proliferation rate was calculated by identification
of tumor area and subsequent count of proliferating nuclei within
the mask made out of the tumor. Relative enrichment of vessels
within the tumors was performed by identification of tumor and
vessel areas and subsequent quantification with an inverse mask
out of tumor area for CD31+ signal. The correlation of the number of
vessels with the CD31+ signal was statistically significant, out of
three tumors quantified (Pearson r = 0.9990; two-tailed P = 0.0289).
For the quantification of vimentin staining, we have used five
different Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D mice from which
we analyzed 21 independent tumors (one section per tumor) and
five different Lgr5-CreERT2;LSL-ALKF1174L mice from which we ana-
lyzed 12 independent tumors. For CD 31 quantification, we used 60
independent Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D tumors (one
section per tumor) and 28 independent Lgr5-CreERT2;LSL-ALKF1174L
tumors (one section per tumor). For Ki67 staining, we used 70 in-
dependent Lgr5-CreERT2;LSL-ALKF1174L;LSL-KrasG12D tumors (one
section each) and 46 independent Lgr5-CreERT2;LSL-ALKF1174L tu-
mors (one section per tumor).
Statistical analysis
Statistical analysis and graphical representation were performed
with GraphPad Prism 5 software. The n reported in the figures or
figure legends always refer to the number of mice used for each
analysis. Column analysis was always performed with t test or
Mann–Whitney test accordingly if the group of data considered in
examination had a normal distribution or not (D’Agostino &
Pearson omnibus normality test). Log-rank (Mantel–Cox) test was
performed for statistical analysis of survivals.
DNA extraction from paraffin tissue and sequencing of Alk exon 23
Paraffin-embedded cSCC from DMBA/TPA–treated mice were kindly
gifted by the Laboratory of Prof. Sabine Werner. A few sections of
tumors were collected in an Eppendorf tube together with 500 μl
lysis buffer, which was incubated at 95°C for 10 min, and then
centrifuged at 4°C, 20.817g for 5 min and the paraffin was removed.
DNA extraction was performed as described above. Exome 23 of Alk
was then amplified using KAPA Taq ReadyMix with dye (KK1024; Kapa
Biosystems) with specific primers (msAlk-ex23_fw: CTATG-
CATCGCCCCAGGAAG, msAlk-ex23_Rv: GGCTGACTCCCAGGAGCCCA;
MT = 60°C), and amplicons were sent for Sanger sequencing to
Microsynth. Sequencing results were analyzed with Sequencer 5.1
(Genecode) and compared with reference sequence downloaded
from Ensembl (www.ensembl.org).
will produce a shorter mRNAmissing exons 18-19-20. White boxes represent exons, arrowheads represent the LoxP sites, and purple lines represent the primers. Below:
RT-PCR analysis of different tissues. Whereas wild-type ear skin shows no detectable expression of Stat3, only 3/6 of the Lgr5-CreERT2;LSL-ALKF1174L;Stat3fl/fl tumors
analyzed show a mixed expression of full-length and truncated Stat3. Number of tumors per mouse in Lgr5-CreERT2;LSL-ALKF1174L and Lgr5-CreERT2;LSL-ALKF1174L;Stat3fl/fl
mice. Mean ± standard error of the mean (5.917 ± 1.026 n = 12, 5.727 ± 1.280 n = 11; two-tailed t test P = 0.9084). (G) Representative immunofluorescence images of Lgr5-
CreERT2;LSL-ALKF1174L, Lgr5-CreERT2;LSL-ALKF1174L;Stat3fl/fl ear tumors immuno-labelled with DAPI, pan-cytokeratin (Pan-Ck), and p-Stat3Y705 antibodies show
phosphorylation of Stat3 within the tumors (above) and in the hyperplastic skin and in the hair follicles (HF) adjacent to the tumor masses (below). To note, all Lgr5-
CreERT2;LSL-ALKF1174L;Stat3fl/fl tumors analyzed (n = 8) showed p-Stat3Y705 expression. Scale bars = 50 µm. (H) From left to right, wild-type ears HFs, and non-hyperplastic
Lgr5-CreERT2;LSL-ALKF1174L and Lgr5-CreERT2;LSL-ALKF1174L;Stat3fl/fl ear HFs adjacent to the tumor masses have been immuno-labelled with DAPI, pan-cytokeratin (Pan-Ck),
and p-Stat3Y705 antibodies. Insets display strong p-Stat3Y705 expression within the HFs of Lgr5-CreERT2;LSL-ALKF1174L mice, whereas wild-type skin is devoid of p-Stat3Y705
expression. Scale bars = 25 µm. Quantification of the recombination was measured as relative number of HFs expressing or not expressing p-Stat3Y705. Only non-
hyperplastic HFs were being considered for the analysis.
Figure 6. A schematic illustration summarizing main findings.
(A) Expression of ALKF1174L in Lgr5+ hair follicle stem cells results in formation of
different skin lesions as Cysts, acanthopapilloma (AP), keratoacanthoma (KA), or
squamous cell carcinoma type 1 (SCC1). Additional KrasG12D expression leads to
increased epithelial to mesenchymal transition, proliferation, and
vascularization. Loss of p53 primes to formation of a more aggressive tumor:
squamous cell carcinoma type 2 (SCC2). Finally, loss of Stat3 prevents the tumor
formation ALKF1174L-induced.
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FACS sorting and RNA sequencing
FACS isolation of ear tumor cells and normal ear keratinocytes
was performed as previously described (Nassar et al, 2015). mRNA
from sorted cells was extracted using the RNeasy Plus Micro Kit
(74034; QIAGEN) according to the manufacturers’ instructions.
Biological replicates from nine independent mice, three Lgr5-
CreERT2;LSL-ALKF1174L, three Lgr5-CreERT2;LSL-ALKF1174L;KrasG12D, and
three Cre− littermates, were sent to the Functional Genomic
Center Zurich for RNA sequencing. RNA-seq-poly-A strategy was
used to build the libraries, and Illumina Novaseq 6000 (Illumina)
was used for sequencing. For following analysis, genes were
selected based on P-value less than 0.01, and Log2 expression fold
change is either above 0.5 or less than −0.5. GO and KEGG signaling
pathways analysis was performed by using Database for Anno-
tation, Visualization, and Integrated Discovery (DAVID) bio-
informatics web tool. Gene Set Enrichment Analysis was
performed against the MSigDB c5.bp.v6.2 gene set and clustering
of enriched biological processes was performed using Cyto-
scape’s EnrichmentMap tool (version 3.2.0). Graphical visualiza-
tion of RNA sequencing data was performed using R (version 3.5.0)
and displayed in terms of Z-score values. RNA-seq data were
deposited and made publicly available on the Gene Expression
Omnibus (GSE147642).
Cell culture
HEK293T cell line (ATCC CRL-3216) was cultured in DMEM Low
Glucose w/L-Glutamine w/Sodium Pyruvate medium (L0060-500;
Dominique Deutscher) enriched with 1.75g D-(+)-glucose (G8270;
Sigma-Aldrich), 10% FCS (S181B-500; Dominique Deutscher), 1%
L-glutamine (25030024; Gibco), and 1% sodium pyruvate (11360-039;
Gibco) and maintained in a humidified incubator at 37°C, 5% CO2.
Transient transfection was performed using Lipofectamine 2000
(11668-019; Thermo Fisher Scientific) according to the manufac-
turers’ protocol. The following plasmids were used: pCMV6-
ALKF1174L-Myc-DDK-tagged (RC400189; OriGene) and pCMV6-Entry
(PS100001; OriGene). 48 h post-transfection, protein extraction
was performed.
Western blot
Proteins were extracted using radio-immunoprecipitation assay
(RIPA) lysis buffer (89900; Thermo Fisher Scientific) containing
cOmplete ULTRA protease inhibitor (05892970001; Roche) and
PhosSTOP (4906837001; Roche) and Phosphatase Inhibitor
Cocktail 2 and 3 (P5726, P0044; Sigma-Aldrich). Cell lysates were
centrifuged for 30 min at 20.817g at 4°C and supernatant was
collected. Protein quantification was performed by Pierce BCA
assay according to the manufacturers’ instructions (23227;
Thermo Fisher Scientific). 30 μg of protein lysates mixed with
Laemmli sample buffer (161-0747; Bio-Rad) was loaded into
Precast Tris–HCl gels, 4–20% (456-8093; Bio-Rad). Trans-Blot
Turbo Transfer System (690BR013492; Bio-Rad) was used to
blot the gel onto polyvinylidene fluoride (PVDF) membranes
(170-4156; Bio-Rad) and subsequently blocked for 1 h in 5% milk
in TBS-T (TBS with 0.1% Tween [P4780-500ML; Sigma-Aldrich]).
Overnight application of the following antibodies diluted in TBS-
T was used: 1:500 Phospho-ALK (Tyr1604) Antibody (3341; Cell
Signaling Technology), 1:1,000 Phospho-STAT3 (T705) Antibody
(9131; Cell Signaling Technology), 1:1,000 Phospho-STAT3 (S727)
Antibody (9134; Cell Signaling Technology), 1:2,000 in GAPDH
Loading Control Monoclonal Antibody (MA5-15738; Thermo Fisher
Scientific), and 1:5,000 Monoclonal anti-α-Tubulin (T-5168;
Sigma-Aldrich). The membranes were washed in TBS-T and
then incubated for 1 h at room temperature with the following
secondary antibodies (1:2,000 in 5% milk in TBS-T): HRP anti-
rabbit IgG (410406; BioLegend) and goat anti-mouse IgG HRP
(405306; BioLegend). The signal was detected by application of
Clarity Western ECL Substrate (170-5060; Bio-Rad) using Fusion
FX VILBER LOURMAT (12-200168).
At least four independent tumors per genotype were subjected
to Western blot analysis.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201900601.
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